ChemoMetec A/S

CPSE:CHEMM Stock Report

Market Cap: DKK 10.5b

ChemoMetec Past Earnings Performance

Past criteria checks 5/6

ChemoMetec has been growing earnings at an average annual rate of 19.7%, while the Life Sciences industry saw earnings growing at 12.8% annually. Revenues have been growing at an average rate of 15.4% per year. ChemoMetec's return on equity is 28.3%, and it has net margins of 36.8%.

Key information

19.7%

Earnings growth rate

19.2%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate15.4%
Return on equity28.3%
Net Margin36.8%
Next Earnings Update07 May 2025

Recent past performance updates

We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

Sep 18
We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

Recent updates

ChemoMetec A/S (CPH:CHEMM) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 08
ChemoMetec A/S (CPH:CHEMM) Analysts Are Pretty Bullish On The Stock After Recent Results

What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

Dec 12
What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

ChemoMetec A/S (CPH:CHEMM) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Nov 09
ChemoMetec A/S (CPH:CHEMM) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

Sep 18
We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You

Jul 29
What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You

Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%

Jul 29
Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%

What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

Jul 03
What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%

Apr 15
Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%

What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling You

Mar 01
What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling You

What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?

Mar 01
What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?

Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 08
Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares

Dec 21
Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Nov 15
Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 17
ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)

Sep 15
A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)

At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?

Jun 20
At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?

With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case

Jun 01
With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case

Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors

Jan 24
Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors

If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity

Oct 26
If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Oct 05
Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?

Jul 18
Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?

Revenue & Expenses Breakdown

How ChemoMetec makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CPSE:CHEMM Revenue, expenses and earnings (DKK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 244601691900
30 Sep 244341531860
30 Jun 244081361810
31 Mar 244051401760
31 Dec 234021441710
30 Sep 234231611660
30 Jun 234441791600
31 Mar 234531791660
31 Dec 224611801710
30 Sep 224451701660
30 Jun 224281591610
31 Mar 223931451470
31 Dec 213581311330
30 Sep 213201101250
30 Jun 21281881180
31 Mar 21262811080
31 Dec 2024374980
30 Sep 2022967980
30 Jun 2021459970
31 Mar 2020654990
31 Dec 19197481010
30 Sep 1918645980
30 Jun 1917642940
31 Mar 1915837860
31 Dec 1814133780
30 Sep 1812725740
30 Jun 1811318690
31 Mar 1810715690
31 Dec 1710213690
30 Sep 179610660
30 Jun 17907640
31 Mar 17886610
31 Dec 16855590
30 Sep 16858540
30 Jun 168510500
31 Mar 168011470
31 Dec 157512440
30 Sep 156810420
30 Jun 15618410
31 Mar 15565380
31 Dec 14513360
30 Sep 14482350
30 Jun 14451330
31 Mar 14441320

Quality Earnings: CHEMM has high quality earnings.

Growing Profit Margin: CHEMM's current net profit margins (36.8%) are higher than last year (35.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CHEMM's earnings have grown by 19.7% per year over the past 5 years.

Accelerating Growth: CHEMM's earnings growth over the past year (17.6%) is below its 5-year average (19.7% per year).

Earnings vs Industry: CHEMM earnings growth over the past year (17.6%) exceeded the Life Sciences industry 17.6%.

Return on Equity

High ROE: CHEMM's Return on Equity (28.3%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/21 20:00
End of Day Share Price 2025/02/21 00:00
Earnings2024/12/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ChemoMetec A/S is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kallum TitchmarshBofA Global Research
null nullDanske Bank
Simon LarssonDanske Bank